Abstract

Objective: In our study we analysed thromboembolic (TE) events of ET patients using data from the Hungarian Myeloproliferative Neoplasm (HUMYPRON) registry. We examined possible thrombosis risk factors and compared Landolfi-, IPSET- and R-IPSET risk stratification models.

Methods: The HUMYPRON registry was estabilished in 2012 and contains data of patients from 14 hungarian haematology centers. We analysed clinical and laboratory data of 237 ET (according to 2008 WHO classification) patients to assess possible risk factors of post-diagnostic TE events and to study the applicability of Landolfi-, IPSET- and R-IPSET thrombosis risk stratifications.

Results: 237 ET patients were followed for 10 years on average. After diagnosis 76 patient (32.1%) had TE complication. Previous thrombotic episode was found to be the only factor that had significant effect on TE events after diagnosis (p<0.001). There were marginally less TE events after diagnosis in case of patients who had extremely high (≥1.000x109/L) platelet count measured at the time of diagnosis (p=0.047). On our sample R-IPSET proved to be the strongest model, where the frequency of TE events was 14.3% in the very low and 46% in the high-risk patient group.

Conclusions: During the follow-up period of 10 years on average, prior TE event was the only factor that had highly significant effect on post-diagnostic thrombosis. Among the risk stratification systems R-IPSET model proved to be the strongest.

Keywords: Essential thrombocythaemia;Thrombosis;Humypron registry;Risk factors; Landolfi; IPSET; R-IPSET

Abbreviations: AMIN:Minor Arterial TE Event; AMAJ: Major Arterial TE Event; VMAJ:Major Venous TE Event; ANA:Anagrelide; HU:Hydroxyurea; ASA:Acetylsalicylic acid